{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:51:52Z","timestamp":1791805912472,"version":"4.3.4"},"reference-count":94,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,19]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Both the 2022 World Health Organization Classification of Hematolymphoid Tumors, 5th Edition and the International Consensus Classification of lymphoma have refined the way we now approach high-grade B-cell lymphoma (HGBL) with MYC and BCL2 and\/or BCL6 rearrangements moving the previous generation of classification a step forward. The unifying biology of MYC\/BCL2 tumors has become clearer and their inferior prognosis confirmed compared with those with morphologic similar phenotypes but lacking the classifcation defining cytogenetic abnormalities. Fluorescent in situ hybridization testing has now become largely population based, and we have learned much from this. We can readily define molecular categories and apply these widely to clinical practice. Uncertainty has, however, been shed on the place of MYC\/BCL6 translocations in defining a common disease group of double hit lymphoma due to biological heterogeneity. We have enhanced our knowledge of outcomes and the role of therapy intensification to overcome chemotherapy resistance in HGBL. For those patients failed by initial induction chemotherapy, immunotherapy approaches, including chimeric antigen receptor T-cell therapies, are improving outcomes. Novel inhibitors, targeting dysregulated oncogenic proteins, are being explored at pace. The rare, but difficult, diagnostic classification HGBL (not otherwise specified) remains a diagnosis of exclusion with limited data on an optimal clinical approach. The days of talking loosely of double- and triple-hit lymphoma are numbered as biology and outcomes may not be shared. This review synergizes the current data on biology, prognosis, and therapies in HGBL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023020780","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T16:58:22Z","timestamp":1729443502000},"page":"2583-2592","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["The high-grade B-cell lymphomas: double hit and\u00a0more"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-6938","authenticated-orcid":false,"given":"Andrew J.","family":"Davies","sequence":"first","affiliation":[{"name":"School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2024121916205352600_bib1","author":"Swerdlow","year":"2017"},{"issue":"11","key":"2024121916205352600_bib2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2024121916205352600_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"6769","key":"2024121916205352600_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"15","key":"2024121916205352600_bib5","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024121916205352600_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"20","key":"2024121916205352600_bib7","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2024121916205352600_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A\u00a0probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"2024121916205352600_bib9","doi-asserted-by":"crossref","first-page":"a008722","DOI":"10.1101\/cshperspect.a008722","article-title":"Multiple functions of BCL-2 family proteins","volume":"5","author":"Hardwick","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"2024121916205352600_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.patbio.2006.04.001","article-title":"The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis","volume":"55","author":"Jardin","year":"2007","journal-title":"Pathol Biol"},{"issue":"5","key":"2024121916205352600_bib11","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/10428190801895345","article-title":"Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas","volume":"49","author":"Parekh","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"2024121916205352600_bib12","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1182\/blood-2013-05-498329","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification","volume":"122","author":"Ott","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2024121916205352600_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/genes8040116","article-title":"The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects","volume":"8","author":"Nguyen","year":"2017","journal-title":"Genes (Basel)"},{"issue":"24","key":"2024121916205352600_bib14","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1002\/cncr.31646","article-title":"Double hit and double expressors in lymphoma: definition and treatment","volume":"124","author":"Riedell","year":"2018","journal-title":"Cancer"},{"issue":"18","key":"2024121916205352600_bib15","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2024121916205352600_bib16","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41375-019-0691-6","article-title":"Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC\/BCL2 double-hit","volume":"34","author":"Cucco","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"2024121916205352600_bib17","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3324\/haematol.2021.279631","article-title":"Mutational landscape of high-grade B-cell lymphoma with MYC-BCL2 and\/or BCL6 rearrangements characterized by whole-exome sequencing","volume":"107","author":"Kunstner","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"2024121916205352600_bib18","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.3324\/haematol.2018.198572","article-title":"Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements","volume":"104","author":"Evrard","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"2024121916205352600_bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024121916205352600_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/PAS.0000000000001750","article-title":"Mutational landscape of TdT+ large B-cell lymphomas supports their distinction from B-lymphoblastic neoplasms: a multiparameter study of a rare and aggressive entity","volume":"46","author":"Bhavsar","year":"2022","journal-title":"Am J Surg Pathol"},{"issue":"35","key":"2024121916205352600_bib21","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024121916205352600_bib22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41408-023-00827-5","article-title":"A\u00a0retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications","volume":"13","author":"El-Sharkawi","year":"2023","journal-title":"Blood Cancer J"},{"issue":"22","key":"2024121916205352600_bib23","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2024121916205352600_bib24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2024121916205352600_bib25","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood.2019002600","article-title":"The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH","volume":"134","author":"Hilton","year":"2019","journal-title":"Blood"},{"issue":"20","key":"2024121916205352600_bib26","first-page":"2493","article-title":"Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population","volume":"141","author":"Alduaij","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2024121916205352600_bib27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2024121916205352600_bib28","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/his.12884","article-title":"MYC\/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis","volume":"68","author":"Li","year":"2016","journal-title":"Histopathology"},{"issue":"1","key":"2024121916205352600_bib29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/10428194.2014.907896","article-title":"TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations","volume":"56","author":"Gebauer","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2024121916205352600_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2023-190316","article-title":"Comparing clinical characteristics and outcomes of MYC and BCL6 double hit lymphoma (DHL- BCL6) with other aggressive B-cell lymphomas: understanding the impact of new WHO and International Consensus Classifications [abstract]","volume":"142","author":"Khurana","year":"2023","journal-title":"Blood"},{"issue":"suppl 2","key":"2024121916205352600_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/hon.3163_134","article-title":"MYC\/BCL6 double hit lymphoma negative for T(3;8) BCL6::MYC fusion is associated with inferior survival, in contrast with T(3;8) positive pseudo-double hit lymphoma","volume":"41","author":"Maybury","year":"2023","journal-title":"Hematol Oncol"},{"key":"2024121916205352600_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.humpath.2018.06.006","article-title":"Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations","volume":"80","author":"Johnson","year":"2018","journal-title":"Hum Pathol"},{"issue":"1","key":"2024121916205352600_bib33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00428-022-03404-6","article-title":"Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma","volume":"482","author":"King","year":"2023","journal-title":"Virchows Arch"},{"issue":"suppl 2","key":"2024121916205352600_bib34","first-page":"111","article-title":"Characterization of the genetic landscape of high-grade B-cell lymphoma, NOS\u2013an LLMPP project","volume":"39","author":"Collinge","year":"2021","journal-title":"Hematol Oncol"},{"issue":"21","key":"2024121916205352600_bib35","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1182\/bloodadvances.2023009731","article-title":"High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study","volume":"7","author":"Zayac","year":"2023","journal-title":"Blood Adv"},{"issue":"28","key":"2024121916205352600_bib36","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"2024121916205352600_bib37","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2024121916205352600_bib38","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical impact of the cell-of-origin classification and the MYC\/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group","volume":"35","author":"Staiger","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2024121916205352600_bib39","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2024121916205352600_bib40","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"15","key":"2024121916205352600_bib41","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2024121916205352600_bib42","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"2024121916205352600_bib43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol"},{"issue":"12","key":"2024121916205352600_bib44","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"21","key":"2024121916205352600_bib45","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024121916205352600_bib46","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3324\/haematol.2022.281461","article-title":"Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double\/triple-hit status in the United States","volume":"108","author":"Goyal","year":"2023","journal-title":"Haematologica"},{"key":"2024121916205352600_bib47","doi-asserted-by":"crossref","first-page":"1188478","DOI":"10.3389\/fonc.2023.1188478","article-title":"Induction treatment in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and\/or BCL6 rearrangement: a systematic review and meta-analysis","volume":"13","author":"Zeremski","year":"2023","journal-title":"Front Oncol"},{"issue":"9","key":"2024121916205352600_bib48","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.annonc.2020.05.016","article-title":"Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M\/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial","volume":"31","author":"McMillan","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"2024121916205352600_bib49","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clml.2014.12.015","article-title":"Outcome of patients with non-Hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M\/IVAC with rituximab followed by hematopoietic stem cell transplantation","volume":"15","author":"Sun","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2024121916205352600_bib50","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ajh.26068","article-title":"First-line treatment of double-hit and triple-hit lymphomas: survival and tolerance data from a retrospective multicenter French study","volume":"96","author":"Laude","year":"2021","journal-title":"Am J Hematol"},{"issue":"11","key":"2024121916205352600_bib51","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines(R) Insights: B-Cell Lymphomas, Version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"9","key":"2024121916205352600_bib52","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/bloodadvances.2020001518","article-title":"Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis","volume":"4","author":"Leppa","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2024121916205352600_bib53","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2024121916205352600_bib54","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.3324\/haematol.2019.238162","article-title":"Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial","volume":"105","author":"Chamuleau","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"2024121916205352600_bib55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2024121916205352600_bib56","author":"Food and Drug Administration","year":"2023"},{"issue":"suppl 1","key":"2024121916205352600_bib57","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1182\/blood-2023-178623","article-title":"Deciphering the clinical benefit of Pola-R-CHP versus R-CHOP in different genetic subtypes beyond cell of origin in the POLARIX study [abstract]","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2024121916205352600_bib58","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5","key":"2024121916205352600_bib59","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/bjh.14100","article-title":"Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704","volume":"174","author":"Puvvada","year":"2016","journal-title":"Br J Haematol"},{"issue":"20","key":"2024121916205352600_bib60","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10216","key":"2024121916205352600_bib61","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"2024121916205352600_bib62","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.2020005846","article-title":"Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP","volume":"137","author":"Freeman","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2024121916205352600_bib63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/bloodadvances.2019000875","article-title":"Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics","volume":"4","author":"Torka","year":"2020","journal-title":"Blood Adv"},{"issue":"35","key":"2024121916205352600_bib64","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1200\/JCO.23.00365","article-title":"High-dose methotrexate as CNS prophylaxis in high-risk aggressive B-cell lymphoma","volume":"41","author":"Lewis","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2024121916205352600_bib65","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2021014506","article-title":"Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients","volume":"139","author":"Wilson","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2024121916205352600_bib66","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00428-023-03590-x","article-title":"Emerging entities: high-grade\/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas: a report of the 2022 EA4HP\/SH lymphoma workshop","volume":"483","author":"Quintanilla-Martinez","year":"2023","journal-title":"Virchows Arch"},{"issue":"2","key":"2024121916205352600_bib67","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bjh.16319","article-title":"Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy","volume":"189","author":"Landsburg","year":"2020","journal-title":"Br J Haematol"},{"issue":"27","key":"2024121916205352600_bib68","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024121916205352600_bib69","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024121916205352600_bib70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"2024121916205352600_bib71","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2024121916205352600_bib72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"18","key":"2024121916205352600_bib73","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2024121916205352600_bib74","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024121916205352600_bib75","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10343","key":"2024121916205352600_bib76","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"suppl 1","key":"2024121916205352600_bib77","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2023-183001","article-title":"Improved survival of R\/R double hit\/triple hit lymphoma in the era of CD19 chimeric antigen T cell (CART) therapy [abstract]","volume":"142","author":"Desai","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2024121916205352600_bib78","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbmt.2017.11.023","article-title":"Outcomes after allogeneic stem cell transplantation in patients with double-hit and double-expressor lymphoma","volume":"24","author":"Herrera","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024121916205352600_bib79","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"24","key":"2024121916205352600_bib80","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024121916205352600_bib81","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024121916205352600_bib82","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2023-179818","article-title":"Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) [abstract]","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121916205352600_bib83","doi-asserted-by":"crossref","first-page":"S431","DOI":"10.1016\/S2152-2650(23)01319-8","article-title":"ABCL-429 epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit\/triple-hit lymphoma: updated EPCORE NHL-2 data","volume":"23","author":"Falchi","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2024121916205352600_bib84","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood.2020006578","article-title":"A\u00a0phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2024121916205352600_bib85","doi-asserted-by":"crossref","first-page":"e818","DOI":"10.1016\/S2352-3026(21)00273-8","article-title":"Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study","volume":"8","author":"Rutherford","year":"2021","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2024121916205352600_bib86","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2021-151266","article-title":"Randomized phase II\/III study of DA-EPOCH-R +\/\u2212 venetoclax in previously untreated double hit lymphoma: initial results from Alliance A051701 [abstract]","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2024121916205352600_bib87","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.23.00033","article-title":"Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up","volume":"41","author":"Davies","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024121916205352600_bib88","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/bloodadvances.2023011369","article-title":"A\u00a0phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen","volume":"8","author":"Karmali","year":"2024","journal-title":"Blood Adv"},{"issue":"14","key":"2024121916205352600_bib89","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/bloodadvances.2020002231","article-title":"BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression","volume":"4","author":"Cummin","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2024121916205352600_bib90","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","article-title":"A\u00a0phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"},{"issue":"4","key":"2024121916205352600_bib91","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"issue":"6","key":"2024121916205352600_bib92","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/s41416-020-01205-9","article-title":"Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax","volume":"124","author":"Herzog","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"2024121916205352600_bib93","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cncr.31791","article-title":"A\u00a0phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer","volume":"125","author":"Eyre","year":"2019","journal-title":"Cancer"},{"issue":"24","key":"2024121916205352600_bib94","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/25\/2583\/2347037\/blood_bld-2023-020780-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/25\/2583\/2347037\/blood_bld-2023-020780-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T11:31:55Z","timestamp":1734607915000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/25\/2583\/518251\/The-high-grade-B-cell-lymphomas-double-hit-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":94,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2024,12,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020780","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]}}}